LONDON, UNITED KINGDOM, June 14, 2018 (GLOBE NEWSWIRE) — Plandaí Biotechnology, Inc. (OTCQB: PLPL) (“Plandaí” or “the Company”), producer of the highly bioavailable Phytofare® catechin complex, today discussed opportunities in the cannabis space and the Company’s efforts to develop the first and only full-profile, non-psychoactive cannabis extract.

Callum Cottrell-Duffield, Chief Operating Officer of Plandaí, released the following statement, “We are one hundred percent focused on getting a full-profile, non-psychoactive cannabis extract product to market.  We believe that with the synergies of the full cannabinoid profile, including the acid precursors of THC and CBD, the extract will yield a finished product with great consumer potential.  Prior research has demonstrated that cannabis, in its natural state, does not have psychotropic properties.  It is the process of heating and drying cannabis that metabolizes the THC-A and THC-B precursors into psychoactive THC.  Our extraction method, which relies of sonoluminescence instead of super-critical extraction, never introduces heat or drying into the process until after the molecules are stabilized.   The resulting product should provide the full potential of cannabis, not just CBD, but without the side effects.  In addition, we expect that our cannabis extract will demonstrate the same high levels of bioavailability as our other extracts, which have been clinically proven to have 15 times greater absorption in the blood stream over generic extracts.  We have the potential to produce an extremely powerful, full-profile, non-psychoactive cannabis product.”

Discussing the medical potential of the product, Mr. Cottrell-Duffield added, “Science is slowly beginning to research and understand the human endo-cannabinoid system.  This system helps modulate a variety of functions, including pain, memory, mood, and locomotor activity.  It is for this reason, we believe, that ingesting cannabis has been linked to improvements across a variety of neural-related problems such as controlling tremors, epilepsy, depression, and pain.  Once we have government approval in South Africa to commence producing our extract, our South African subsidiary plans to immediately establish a controlled-growing and extraction facility.  Our extract will then be thoroughly validated with respect to composition, bioavailability and non-psychoactivity.”

Mr. Cottrell-Duffield concluded, “We are convinced that consumers will gladly welcome a highly bioavailable full profile cannabis extract, that doesn’t come with any psychoactive side effects. We believe our extraction technology, in conjunction with our Phytofare Catechin Complex, that has been clinically shown to increase the bioavailability of plant catechins in the blood-stream for more than 24 hours, holds significant promise for a wide variety of  consumer based  products, especially as the legal and societal barriers to the acceptance of cannabis continue to fall by the wayside worldwide.”

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company’s products include animal husbandry, dietary supplements, diabetes and cannabis. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit:

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company’s filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.